Displaying 1–25 of 40 results for Paul Thomas, Contributing Editor
By better combining and interpreting readily available data, biomanufacturing experts are improving control of fermentation and other processes, says Sartorius Roland Bienert.
By better combining and interpreting readily available data, biomanufacturing experts are gaining better control of fermentation and other processes, says Sartorius Roland Bienert
By better combining and interpreting readily available data, biomanufacturing experts are gaining better control of fermentation and other processes, says Sartorius Roland Bienert.
Can standardization and innovation coexist?
Efforts to enact meaningful standards for single-use bioprocessing technologies move at a snail's pace, with no clear path forward, experts say.
Janet Woodcock looks forward to having more cash and resources with new user fee legislation. Meanwhile, she raises concerns about the Agencys authority over biosimilars should the Supreme Court strike down the Affordable Care Act.
An interview with Thomas Schilling on the companys Green IT initiative.
Drug industry environmental stewardship projects are becoming more sophisticated and challenging. Here are examples from AstraZeneca, Bayer, DSM, Pfizer, and EMD Millipore
A talk with sustainability manager Johanna Jobin about the company's new product recycling initiative.
West and Vetter look to meet the needs of parenteral manufacturers demanding new, safer syringe options.
Organizations with built-in risk management frameworks allow middle managers to thrive, says Scott Chizzo, Maxiom Groups president and chief consultant, in this exclusive interview.
Consultant Steve Sawin answers our questions about managing contingent labor.
It may be hard to find good help, but its also hard to find good work.
If Ashton Kutcher were in pharma, hed be on LinkedIn.
Manufacturers must practice a heightened sense of "Pharmecovigilance" regarding drug compounds leaving their facilities as waste, says a leading expert.
Lean Six Sigma, expertise in microbiology, and shop-floor experience all contribute to running a flexible, efficient contract facility, says DPTs new director of sterile ops.
Compliance specialist Michael Gregor puts the spotlight on software validation, and tells us why FDA is doing the same.
The need to improve agility and reduce financial risk is driving new approaches to plant design and operation, and the use of new technologies. Industry experts look at the future pharmaceutical plant from all angles.
Big Pharma has gone green, but smaller manufacturers have yet to flip the switch, say industry experts and our own survey.
This is no me-too effort, PDAs Levy says.
Pfizer Singapore site leader Stella Eccles talks about making gabapentin (Neurontin) green, and keeping its production viable.
For a specialized show, IFPAC 2009 is a lot to take in.
Dr. Harold McNair was there when gas chromatography began, but considers his greatest achievements to have come as a teacher and mentor.
Microreactors are challenging the concept of "economies of scale."